[Courtesy of EOFlow]
SEOUL -- An innovative wearable and disposable insulin pump developed by EOFlow, a provider of wearable drug delivery solutions, made its debut in South Korea. It is the world’s second commercial product of its kind, the company said, promising to push for early overseas sales.
EOPatch, which is used to continuously deliver insulin in blood glucose control, provides an alternative to users in the market monopolized by Insulet Corporation, a medical device company headquartered in Massachusetts, the South Korean company said, adding its product is easier to use.
EOFlow said that key advantages of its product include a small and light design that drastically reduces size and weight, waterproof, the long-wear time to allow twice-a-week compliance and faster needle insertion for reduced insertion pain.
"Our aim is to make our product available and accessible to all the MDI (multiple daily injection) insulin users around the world," EOFlow CEO Jesse Kim said in a statement on March 29. "We are confident that EOPatch will overcome the limitations of conventional insulin pumps and position itself as an innovative digital medical device to address the unmet needs in insulin delivery."
Park Cheol-young, a professor of internal medicine at Sungkyunkwan University School of Medicine, described wearable insulin pumps as a key innovation driver that brings in "another paradigm shift." "EOPatch will improve insulin users’ quality of life with its key competitiveness such as improved compliance and cost advantage," he said.
EOPatch can be replaced at a set time and used low-power high-performance electric osmosis pump technology. The product consists of a wearable insulin pump, a smartphone-like controller called "ADM" and diabetes management software. The history of injection can be stored for up to 90 days. Data synced to the app or web for analysis can be shared with guardians or medical personnel.
reporter
Lim Chang-won
cwlim34@ajunews.com
